Manufacturing process for pyrimidine derivatives

Patent metadata

Field	Value
Publication number	US-9452994-B2
Application number	US-201615147986-A
Country	US
Kind code	B2
Filing date	May 6, 2016
Priority date	Oct 1, 2010
Publication date	Sep 27, 2016
Grant date	Sep 27, 2016

Abstract

The invention relates to processes for manufacturing a compound of formula 5,

or a stereoisomer, tautomer or a salt thereof, wherein the substituents are as defined in the specification. The invention further relates to new manufacturing processes for specific solid forms of Compound A and its salts, to such solid forms and to use of such solid forms for the therapeutic treatment of warm-blooded animals.

First claim

The invention claimed is:

1. A process for manufacturing a compound of formula 5,

or a stereoisomer, tautomer, or a salt thereof, comprising the following steps:
Step A: contacting a compound of formula B1

with a reaction mixture comprising a solvent selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents and ethereal solvents and an acid anhydride (R 5 C═O) 2 O, such that a compound of formula B2 is produced

Step B: i) contacting a compound of formula B2 with a reaction mixture comprising a first solvent selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents and ethereal solvents, a first base selected from lithium amide, lithium dialkylamides, lithium alkoxides and isomers of butyllithium and optionally an alcohol additive, ii) contacting the mixture of step (i) with a second solvent selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents and ethereal solvents and a second base selected from isomers of butyllithium and Grignard reagents, iii) contacting the mixture of step (ii) with a boric acid derivative, iv) optionally contacting the mixture of step (iii) with a third solvent selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents and ethereal solvents and a third base selected from isomers of butyllithium and Grignard reagents and then contacting the resulting mixture with a boric acid derivative, and v) optionally contacting the mixture of step (iii) or step (iv) with water and acid, such that a compound of formula B3 is produced:

Step C: contacting a compound of formula B3 with a reaction mixture comprising a solvent selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents, ethereal solvents and water, a base selected from acetates, phosphates and carbonates, a catalyst, and a compound of formula 3

such that a compound of B5 is produced

Step D: contacting a compound of formula B5 with a reaction mixture comprising a solvent selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents, ethereal solvents and water and a reagent for the removal of the R 5 C(═O)— moiety selected from acids, bases and metal catalysts, such that a compound of formula 5 is produced;
optionally followed by a salt forming reaction;
wherein,
W represents CH;
R 1 represents N-morpholinyl;
R 2 represents hydrogen;
R 3 represents trifluoromethyl;
R 4 represents hydrogen; and
R 5 is selected from the group consisting of (1) hydrogen, (2) substituted or unsubstituted alkyl, (3) substituted or unsubstituted alkyloxy, (4) substituted or unsubstituted aryl, (5) substituted or unsubstituted aryloxy, (6) substituted or unsubstituted arylalkyloxy;
BY 2 represents a boronic acid, an acyclic boronic ester, a cyclic boronic ester, or a trifluoroborate salt; and
Hal represents halogen.

2. The process of claim 1 wherein
R 5 represents methyl.

3. The process of claim 1 , wherein Step C is conducted under Suzuki conditions involving the presence of the Pd-catalyst Pd(PPh 3 ) 4 .

4. The process of claim 1 , wherein the solvent of Step A comprises one or more solvents selected from ethyl acetate and heptane.

5. The process of claim 1 , wherein the first, second and third solvents of Step B independently comprise one or more solvents selected from THF and hexane.

6. The process of claim 1 , wherein the first base of Step B is lithium amide.

7. The process of claim 1 , wherein the second and third bases of Step B are n-butyllithium.

8. The process of claim 1 , wherein the boric acid derivative of Step B is triisopropylborate.

9. The process of claim 1 , wherein the solvent of Step C comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1,4-dioxane, 2-methyl-tetrahydrofuran and water.

10. The process of claim 1 , wherein the base of Step C is potassium carbonate.

11. The process of claim 1 , wherein the catalyst of Step C is selected from tetrakis(triphenylphosphine)palladium (0) and bis(triphenylphosphine)palladium (II) dichloride.

12. The process of claim 1 , wherein the reagent for the removal of the R 5 C(═O)— moiety in Step D is hydrochloric acid.

13. The process of claim 1 , wherein R 5 represents methyl and wherein:
(a) Step C is conducted under Suzuki conditions involving the presence of the Pd-catalyst Pd(PPh 3 ) 4 ,
(b) the solvent of Step A comprises one or more solvents selected from ethyl acetate and heptane,
(c) the first, second and third solvents of Step B independently comprise one or more solvents selected from THF and hexane,
(d) the first base of Step B is lithium amide,
(e) the second and third bases of Step B are n-butyllithium,
(f) the boric-acid derivative of Step B is triisopropylborate,
(g) the solvent of Step C comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1,4-dioxane, 2-methyl-tetrahydrofuran and water,
(h) the base of Step C is potassium carbonate,
(i) the catalyst of Step C is selected from tetrakis(triphenylphosphine)palladium (0) and bis(triphenylphosphine)palladium (II) dichloride, and
(j) the reagent for the removal of the R 5 C(═O)— moiety in Step D is hydrochloric acid.

Assignees

• Flubacher Dietmar
• Michel Pascal
• Testa Maria Caterina
• Mose Rasmus
• Novartis Ag

Inventors

• Flubacher Dietmar
• Michel Pascal
• Testa Maria Caterina
• Mose Rasmus

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61P13/08

  of the prostate · CPC title